Rh-endostatin in Combination with Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

Objective To evaluate the treatment efficacy and safety with the combination of rh-endostatin(YH-16) and chemotherapy in patients with advanced non-small cell lung cancer(NSCLC). Methods 34 patients with advanced non-small cell lung cancer confirmed by histopathology or cytopathology were administrated with YH-16 7.5mg/m² (day 1~14) and routine chemotherapy every 3 weeks.The dosage of (8.3~10)mg/m² (15mg/time) of rh-endostatin solved in 500ml normal saline was slowly intravenously dropped for 3~4 hours from 1 to 14 days, repeated after 7days. The overall response and toxicity were observed. Results Totally, 34 patients were entered and all of these patients were evaluated.Partial response was observed in 9 patients,stable disease was observed in 19 patients and progressive disease was observed in 6 patients. Overall response rate was 26.47%（9/34）, Clinical benefit rate was 82.35%（28/34）.For the untreated patients and the pretreated patients,the response rate was 42.86% and 15%（P<0.05）, Clinical benefit rate was 92.86% and 75%（P<0.05）, respectively.No serious adverse event was observed. Conclusion The rh-endostatin combined with chemotherapy tends to show a better treatment efficacy than chemotherapy alone and is well tolerated in patients with advanced non-small cell lung cancer patients,especially in the front line treatment.